Ir-Med Inc Stock Price, News & Analysis

IR-MED has announced a partnership with Rabin Medical Center to expand usability studies for its PressureSafe device, aimed at improving the early detection of pressure injuries (PI) in patients. This device utilizes Infrared light spectroscopy and AI, demonstrating potential for significant health benefits, especially for individuals with darker skin tones who are at higher risk for PIs. The collaboration with RMC, a prominent hospital known for its research and accreditation, will enhance the study's scope and credibility. The company emphasizes the potential economic impact of PIs, with U.S. costs exceeding $26.8 billion annually.

IR-MED (OTC-PINK:IRME) has achieved significant advancements in 2022 and is preparing for a U.S. market launch in 2023. The company has completed its PressureSafe device, designed for early detection of pressure injuries, aiming to improve healthcare outcomes and reduce costs. An exclusive distribution agreement with PI Prevention Care LLC will enhance market penetration. Additionally, IR-MED is developing Nobiotics, a handheld device for diagnosing ear infections. The company raised $3.6M in late 2022, enhancing its financial position, and plans to seek FDA approval for PressureSafe in the latter half of 2023.

IR-MED (OTCQB:IRME) announced the appointment of Dr. David Dalton to its Advisory Board. Dr. Dalton, a prominent figure in healthcare with a track record of founding over 40 companies, will contribute insights on the PressureSafe device, aimed at early detection of pressure injuries (PI). His expertise is particularly relevant for enhancing care in Hispanic and African American populations, who are at a higher risk for PIs. Dr. Dalton's experience includes leadership roles in significant pharmaceutical organizations and a focus on minority health initiatives, further aligning with IR-MED's mission.

IR-MED (OTCQB: IRME) has announced a new agreement with Bina Industrial Design Ltd for the commercial design of its PressureSafe device, aimed at detecting early-stage pressure injuries. This partnership will utilize feedback from a usability study currently in progress in Israel to enhance the device's design. PressureSafe employs advanced spectrographic analysis and AI to identify conditions that may lead to pressure injuries, a significant concern in healthcare, with 60,000 related fatalities annually in the US.

IR-MED (OTCQB: IRME), a medical device innovator, has submitted a provisional patent application for its PressureSafe device, which aims to detect early-stage pressure injuries (PIs) using advanced infrared spectroscopy and AI. This development is crucial as PIs pose significant health risks, with around 60,000 related mortalities in the US annually and costs exceeding $26.8 billion. The PressureSafe device is set for usability studies in Israel, offering timely intervention data that could drastically improve patient outcomes and reduce hospital-related penalties for untreated PIs.

IR-MED, operating as a development stage medical device company, has signed a study agreement with Beit Rivka, a prominent Geriatric Hospital in Israel. This collaboration will focus on a usability study for their innovative device, PressureSafe, designed to aid in the early detection of pressure injuries (PI). This device utilizes AI technologies for real-time monitoring, targeting a significant health issue faced by care providers. The annual cost related to hospital-acquired pressure injuries in the US exceeds $26.8 billion, underlining the importance of preventative measures in healthcare facilities.

IR-MED has appointed Moshe Gerber as the new Chief Executive Officer, effective immediately. Mr. Gerber brings over 25 years of experience in international business development, particularly in the medical device sector. He previously founded Gerium Medical, which developed jaundice measurement devices, and later sold it to Mennen Medical. His focus on innovation and growth positions IR-MED favorably as they develop non-invasive detection technologies. The company is pioneering a optical monitoring device aimed at early detection of pressure injuries.

IR-Med, a medical device company, announced a Subscription Agreement for the sale of 3,636,364 shares at $0.88 per share and warrants for another 3,636,364 shares at $1.10 each, resulting in gross proceeds of $3,200,000. CEO Dr. Rom Eliaz stated that this funding strengthens their balance sheet and facilitates future developments. The proceeds will support general corporate purposes and product development. The company is focused on non-invasive technology for real-time blood and tissue analysis, targeting early detection of pressure injuries.

IR-Med has announced its approval to up-list from Pink Sheets to the OTCQB tier, effective February 1, 2022. This transition reflects the company’s compliance with enhanced financial reporting and transparency standards required by the OTCQB marketplace. CEO Dr. Rom Eliaz emphasized that this listing will bolster investor awareness and support the company’s growth strategy. IR-Med is focused on developing non-invasive spectral analysis technology for healthcare applications, including monitoring pressure injuries.